{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:36:19Z","timestamp":1786653379654,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol India"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0028-3886.152631","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T02:33:52Z","timestamp":1425436432000},"page":"35","source":"Crossref","is-referenced-by-count":15,"title":["Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy"],"prefix":"10.4103","volume":"63","author":[{"given":"Sheffali","family":"Gulati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaram","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kaleekal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhulika","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerja","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YK","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RavindraMohan","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0028-3886.152631-1","first-page":"357","volume-title":"Defining the clinical role of pharmacogenetics in antiepileptic drug therapy","author":"Dlugos","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"key-10.4103\/0028-3886.152631-2","first-page":"189","volume-title":"Update on pharmacogenetics in epilepsy: A brief review","author":"Szoeke","year":"2006","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/0028-3886.152631-3","unstructured":"Levy RH, Mattson RH, Meldrum BS, Perucca B. In: Levy R, Mattson B, Meldrum B, editors. Antiepileptic Drugs. 5 th ed. Philadelphia: Lippincott Williams and Wilkins; 2002."},{"key":"key-10.4103\/0028-3886.152631-4","first-page":"1441","volume-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","author":"Ethell","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"key-10.4103\/0028-3886.152631-5","first-page":"320","volume-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","author":"Tan","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"key-10.4103\/0028-3886.152631-6","first-page":"335","volume-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"key-10.4103\/0028-3886.152631-7","first-page":"927","volume-title":"Indian Genome Variation Consortium.Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment","author":"Grover","year":"2010","journal-title":"Pharmacogenomics"},{"key":"key-10.4103\/0028-3886.152631-8","first-page":"485","volume-title":"Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: Pharmacological implications","author":"Ciotti","year":"1997","journal-title":"Pharmacogenetics"},{"key":"key-10.4103\/0028-3886.152631-9","first-page":"487","volume-title":"Human UGT1A6 pharmacogenetics: Identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells","author":"Nagar","year":"2004","journal-title":"Pharmacogenetics"},{"key":"key-10.4103\/0028-3886.152631-10","first-page":"1331","volume-title":"UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I.Identification of polymorphisms in the 5\u2032-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation","author":"Krishnaswamy","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/0028-3886.152631-11","first-page":"429","volume-title":"Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan","author":"Wang","year":"2010","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"key-10.4103\/0028-3886.152631-12","first-page":"2033","volume-title":"Effect of UGT1A6 genetic polymorphisms on the metabolism of sodium valproate","author":"Sun","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"key-10.4103\/0028-3886.152631-13","first-page":"1107","volume-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","author":"Hung","year":"2011","journal-title":"Pharmacogenomics"},{"key":"key-10.4103\/0028-3886.152631-14","first-page":"1395","volume-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","author":"Chu","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.4103\/0028-3886.152631-15","first-page":"536","volume-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"key-10.4103\/0028-3886.152631-16","first-page":"470","volume-title":"Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"key-10.4103\/0028-3886.152631-17","first-page":"149","volume-title":"Genetic Power Calculator: Design of linkage and association genetic mapping studies of complex traits","author":"Purcell","year":"2003","journal-title":"Bioinformatics"},{"key":"key-10.4103\/0028-3886.152631-18","first-page":"741","volume-title":"Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling","author":"Xing","year":"2009","journal-title":"Pharmacogenomics"},{"key":"key-10.4103\/0028-3886.152631-19","first-page":"85","volume-title":"Genetic polymorphisms of UGT1A6 in a Japanese population","author":"Saeki","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"key-10.4103\/0028-3886.152631-20","first-page":"341","volume-title":"UDP-glucuronosyltransferase (UGT1A1 FNx01 28 and UGT1A6 FNx01 2) polymorphisms in Caucasians and Asians: Relationships to serum bilirubin concentrations","author":"Lampe","year":"1999","journal-title":"Pharmacogenetics"},{"key":"key-10.4103\/0028-3886.152631-21","first-page":"319","volume-title":"The effect of uridine diphosphate glucuronosyltransferase (UGT) 1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: A pharmacogenetic approach","author":"Munisamy","year":"2013","journal-title":"Mol Diagn Ther"}],"container-title":["Neurology India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:36:18Z","timestamp":1786649778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.152631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"alternative-id":["152631"],"URL":"https:\/\/doi.org\/10.4103\/0028-3886.152631","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}